ClearanceBrief
Recall Z-2547-2020 ยท OQO Herpes Simplex Virus Nucleic Acid Amplification Assay

DiaSorin Molecular LLC

MOL2150 Simplexa HSV 1&2 Direct -CSF -Genital Swab -Cutaneous / Mucocutaneous Swabs Product Usage: is intended for use on the LIAISON MDX instrument for the qualitative detection and differentiation of HSV-1 and HSV-2 present in cerebrospinal fluid (CSF), or cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of HSV-1 or HSV-2 infection of the central nervous system (CNS

DateJul 10, 2020 (initiated May 12, 2020)
StatusTerminated
ReasonDue to a software malfunction in the Multi Assay Suite, there is the probability of increased occurrence of false negative results.
Root causeUnder Investigation by firm
ActionOn 05/12/2020, the firm sent an "URGENT FIELD SAFETY NOTIFICATION LETTER" with an acknowledgement form to customers and distributors via email to inform them of an internal observed issue associated with the use of their Multi-Assay Suite (MAS) featured in the software version 2.0 where it may incorrectly apply the thresholds of the first loaded assay to the analytes coupled with the same dye in the second assay resulting in false negative or false positive results. The firm is instructing customers to: -Immediately discontinue the use of the MAS feature and that the issue will be correct in
Quantity13943 plastic vials (24 vials per box)
DistributionWorldwide distribution - U.S. Nationwide distribution including in the states of CO, FL, KS, MI, NC, PA, TX, and WA The countries of Austria, Czech Republic, France and Switerland.
FDA recordOpen on fda.gov

510(k) clearances named in this recall

K141458SIMPLEXA HSV 1&2 DIRECT/POSITIVE CONTROL PACK
Focus Diagnostics, Jul 1, 2014
K150962Simplexa HSV 1 & 2 Direct, Simplexa HSV 1 & 2 Positive Control Pack
Focus Diagnostics, Aug 28, 2015